Literature DB >> 9408919

Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity.

N B Farber1, J Hanslick, C Kirby, L McWilliams, J W Olney.   

Abstract

Phencyclidine, ketamine, and other agents that block NMDA glutamate receptors trigger a schizophrenia-like psychosis in humans and induce pathomorphological changes in cerebrocortical neurons in rat brain. Accumulating evidence suggests that a complex network disturbance involving multiple transmitter receptor systems is responsible for the neuronal injury, and it is proposed that a similar network disturbance is responsible for the psychotomimetic effects of NMDA antagonists, and might also be involved in the pathophysiology of schizophrenia. In the present study we present evidence that serotonergic agents possessing 5HT2A agonist activity prevent NMDA antagonist neurotoxicity in rat brain. It is proposed that 5HT2A agonists may also prevent the psychotomimetic effects of NMDA antagonists. Among the 5HT2A agonists examined and found to be neuroprotective are LSD and related hallucinogens. The apparent contradiction in proposing that these agents might have antipsychotic properties is resolved by evidence linking their hallucinogenic activity to agonist action at 5HT2C receptors, whereas antipsychotic activity would be attributable to agonist action at 5HT2A receptors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9408919     DOI: 10.1016/S0893-133X(97)00127-9

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  8 in total

Review 1.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 2.  Treatment of negative and cognitive symptoms.

Authors:  D C Javitt
Journal:  Curr Psychiatry Rep       Date:  1999-10       Impact factor: 5.285

3.  Antagonism of phencyclidine-induced stimulus control in the rat by other psychoactive drugs.

Authors:  J C Winter
Journal:  Pharmacol Biochem Behav       Date:  2007-08-15       Impact factor: 3.533

4.  Pimavanserin, a 5HT2A receptor inverse agonist, rapidly suppresses Aβ production and related pathology in a mouse model of Alzheimer's disease.

Authors:  Carla M Yuede; Clare E Wallace; Todd A Davis; Woodrow D Gardiner; Jane C Hettinger; Hannah M Edwards; Rachel D Hendrix; Brookelyn M Doherty; Kayla M Yuede; Ethan S Burstein; John R Cirrito
Journal:  J Neurochem       Date:  2021-01-10       Impact factor: 5.372

5.  NMDA receptor function, memory, and brain aging.

Authors:  J W Newcomer; N B Farber; J W Olney
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

Review 6.  Environmental agents that have the potential to trigger massive apoptotic neurodegeneration in the developing brain.

Authors:  J W Olney; N B Farber; D F Wozniak; V Jevtovic-Todorovic; C Ikonomidou
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

7.  Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin.

Authors:  Michael M Schartner; Robin L Carhart-Harris; Adam B Barrett; Anil K Seth; Suresh D Muthukumaraswamy
Journal:  Sci Rep       Date:  2017-04-19       Impact factor: 4.379

8.  REL-1017 (Esmethadone), A Novel NMDAR Blocker for the Treatment of MDD is Not Neurotoxic in Sprague-Dawley Rats.

Authors:  Francesco Bifari; Marco Pappagallo; Michael Bleavins; Sergio Traversa; Franco Folli; Paolo L Manfredi
Journal:  Front Pharmacol       Date:  2022-04-25       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.